comparemela.com

Latest Breaking News On - Aruvant sciences - Page 8 : comparemela.com

Aruvant Appoints Stan Musial as Chief Financial Officer

  NEW YORK and BASEL, Switzerland, June 28, 2021 /PRNewswire/ Aruvant Sciences, a private company focused on developing gene therapies for rare diseases, today announced the appointment of Stanley J. Musial as chief financial officer (CFO) effective immediately. Mr. Musial brings over twenty-five years of experience building corporate value through operational execution, financial strategy and capital fundraising. Stan s expertise in managing financials and raising capital at both private and public biotechnology companies comes at an important time as Aruvant goes through substantial growth, said Will Chou, M.D., chief executive officer of Aruvant. Stan is a critical addition to our leadership team as we put the infrastructure in place needed to support the development of our pipeline of potentially life changing gene therapies for individuals living with rare diseases.

Aruvant Announces Oral Presentation at 15th Annual Sickle Cell Disease Research & Educational Symposium & 44th National Sickle Cell Disease Scientific Meeting

Aruvant Sciences ("Aruvant"), a private company focused on developing gene therapies for rare diseases, today announced that data on ARU-1801, a potentially curative lentiviral gene therapy for sickle cell disease (SCD), will be delivered in an oral presentation at the 15th Annual Sickle Cell Disease Research & Educational Symposium & 44th National Sickle Cell Disease Scientific Meeting. Dr. Monika Asnani, professor of family medicine & epidemiology at the Caribbean Institute for Health Research, will present data from the ARU-1801 Phase 1/2 MOMENTUM clinical trial during the meeting which will take place virtually from May 27 to May 30, 2021.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.